Table 3.
Pharmacokinetic parameters and ratios based on geometric least squares means
| Treatment group | |||
|---|---|---|---|
| Study 1 | Esaxerenone (n = 22) | + Amlodipine (n = 22) | Ratio (90% CI) |
| Cmax, ng/mL | 35.0 | 33.5 | 0.958 (0.905, 1.015) |
| AUClast, ng·h/mL | 551 | 635 | 1.154 (1.118, 1.190) |
| AUCinf, ng·h/mL | 565 | 663 | 1.173 (1.136, 1.212) |
| Study 2 | Amlodipine (n = 18) | + Esaxerenone (n = 18) | Ratio (90% CI) |
| Cmax, ng/mL | 2.04 | 2.24 | 1.099 (1.059, 1.140) |
| AUClast, ng·h/mL | 84.4 | 100 | 1.185 (1.132, 1.240) |
| AUCinf, ng·h/mL | 97.6 | 118 | 1.214 (1.157, 1.273) |
| Study 3 | Digoxin (n = 19) | + Esaxerenone (n = 19) | Ratio (90% CI) |
| Cmax, ng/mL | 1.47 | 1.66 | 1.130 (0.998, 1.280) |
| Ctrough, ng/mL | 0.526 | 0.572 | 1.088 (1.033, 1.145) |
| AUCtau, ng·h/mL | 15.1 | 16.2 | 1.072 (1.015, 1.133) |
AUCinf area under the plasma concentration–time curve up to infinity, AUClast AUC up to the last quantifiable time, AUCtau AUC over the dosing interval, CI confidence interval, Cmax peak plasma concentration, Ctrough trough plasma concentration